A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

This early-phase study tests a new targeted antibody drug called OM-RCA-01 — which targets a protein called FGFR1 that is overexpressed on some tumor cells — alone or in combination with other therapies, in people with several types of advanced solid tumors. **You may be eligible if...** - You are 18 or older and weigh at least 50 kg - You have advanced metastatic cancer that is one of the following: clear-cell kidney cancer, non-small cell lung cancer (non-EGFR/ALK), castration-resistant prostate cancer, breast cancer, or head and neck squamous or salivary gland cancer - Your tumor has high (2+ or greater) expression of the protein FGFR1 on immunohistochemistry testing - Your cancer has progressed after at least two prior lines of standard treatment, or no good alternatives remain **You may NOT be eligible if...** - Your tumor does not express FGFR1 sufficiently - You have not yet tried available standard therapies Talk to your doctor to see if this trial is right for you.